CoChat

PEPD is a pivotal regulator of p53 tumor suppressor

Yang, Lu, Li, Yun, Bhattacharya, Arup, Zhang, Yuesheng · 2017 · Nature Communications
Cited by 29

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

p53 tumor suppressor responds to various cellular stresses and regulates cell fate. Here, we show that peptidase D (PEPD) binds and suppresses over half of nuclear and cytoplasmic p53 under normal conditions, independent of its enzymatic activity. Eliminating PEPD causes cell death and tumor regression due to p53 activation. PEPD binds to the proline-rich domain in p53, which inhibits phosphorylation of nuclear p53 and MDM2-mediated mitochondrial translocation of nuclear and cytoplasmic p53. However, the PEPD-p53 complex is critical for p53 response to stress, as stress signals doxorubicin and H 2 O 2 each must free p53 from PEPD in order to achieve robust p53 activation, which is mediated by reactive oxygen species. Thus, PEPD stores p53 for the stress response, but this also renders cells dependent on PEPD for survival, as it suppresses p53. This finding provides further understanding of p53 regulation and may have significant implications for the treatment of cancer and other diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-017-02097-9

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 51

  1. Bergmann, M. & Fruton, J. S. On proteolytic enzymes: XII. Regarding the specificity of aminopeptidase and carboxypeptidase. A new type of enzyme in the intestinal tract. J. Biol. Chem. 117, 189–202 (1937). · doi:10.1016/s0021-9258(18)74600-0
  2. Myara, I., Charpentier, C. & Lemonnier, A. Prolidase and prolidase deficiency. Life Sci. 34, 1985–1998 (1984). · DOI
  3. Lupi, A. et al. Human recombinant prolidase from eukaryotic and prokaryotic sources. Expression, purification, characterization and long-term stability studies. FEBS J. 273, 5466–5478 (2006). · doi:10.1111/j.1742-4658.2006.05538.x
  4. Surazynski, A. et al. Extracellular matrix and HIF-1 signaling: the role of prolidase. Int. J. Cancer 122, 1435–1440 (2008). · DOI · Paper page
  5. Surazynski, A., Miltyk, W., Palka, J. & Phang, J. M. Prolidase-dependent regulation of collagen biosynthesis. Amino Acids 35, 731–738 (2008). · DOI · Paper page
  6. Kitchener, R. L. & Grunden, A. M. Prolidase function in proline metabolism and its medical and biotechnological applications. J. Appl. Microbiol. 113, 233–247 (2012). · DOI · Paper page
  7. Lupi, A., Tenni, R., Rossi, A., Cetta, G. & Forlino, A. Human prolidase and prolidase deficiency: an overview on the characterization of the enzyme involved in proline recycling and on the effects of its mutations. Amino Acids 35, 739–752 (2008). · DOI
  8. Yang, L. et al. Prolidase directly binds and activates epidermal growth factor receptor and stimulates downstream signaling. J. Biol. Chem. 288, 2365–2375 (2013). · doi:10.1074/jbc.m112.429159
  9. Yang, L., Li, Y. & Zhang, Y. Identification of prolidase as a high affinity ligand of the ErbB2 receptor and its regulation of ErbB2 signaling and cell growth. Cell Death Dis. 5, e1211 (2014). · DOI
  10. Yang, L., Li, Y., Bhattacharya, A. & Zhang, Y. Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D. Oncotarget 7, 42340–42352 (2016). · DOI
  11. Yang, L., Li, Y., Bhattacharya, A. & Zhang, Y. A plasma proteolysis pathway comprising blood coagulation proteases. Oncotarget 7, 40919–40938 (2016). · DOI
  12. Yang, L., Li, Y., Bhattacharya, A. & Zhang, Y. Inhibition of ERBB2-overexpressing tumors by recombinant human prolidase and its enzymatically inactive mutant. EBioMedicine 2, 396–405 (2015). · DOI
  13. Lubick, K. J. et al. Flavivirus antagonism of type I interferon signaling reveals prolidase as a regulator of IFNAR1 surface expression. Cell Host Microbe 18, 61–74 (2015). · DOI · Paper page
  14. Grossman, H. B., Wedemeyer, G., Ren, L., Wilson, G. N. & Cox, B. Improved growth of human urothelial carcinoma cell cultures. J. Urol. 136, 953–959 (1986). · DOI
  15. Ledoux, P., Scriver, C. R. & Hechtman, P. Expression and molecular analysis of mutations in prolidase deficiency. Am. J. Hum. Genet. 59, 1035–1039 (1996).
  16. Fan, Y. X., Wong, L., Deb, T. B. & Johnson, G. R. Ligand regulates epidermal growth factor receptor kinase specificity: activation increases preference for GAB1 and SHC versus autophosphorylation sites. J. Biol. Chem. 279, 38143–38150 (2004). · DOI
  17. Bunz, F. et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497–1501 (1998). · DOI · Paper page
  18. Li, Y. et al. A novel dithiocarbamate derivative induces cell apoptosis through p53-dependent intrinsic pathway and suppresses the expression of the E6 oncogene of human papillomavirus 18 in HeLa cells. Apoptosis 20, 787–795 (2015). · doi:10.1007/s10495-015-1114-4
  19. Komarova, E. A. et al. p53 inhibitor pifithrin alpha can suppress heat shock and glucocorticoid signaling pathways. J. Biol. Chem. 278, 15465–15468 (2003). · DOI · Paper page
  20. Rieger, K. M. et al. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br. J. Cancer 72, 683–690 (1995). · DOI
  21. Vaseva, A. V. & Moll, U. M. The mitochondrial p53 pathway. Biochim. Biophys. Acta 1787, 414–420 (2009). · DOI · Paper page
  22. el-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817–825 (1993). · DOI · Paper page
  23. Maher, M. J. et al. Structure of the prolidase from Pyrococcus furiosus. Biochemistry 43, 2771–2783 (2004). · doi:10.1021/bi0356451
  24. Besio, R. et al. Identifying the structure of the active sites of human recombinant prolidase. Eur. Biophys. J. 39, 935–945 (2010). · doi:10.1007/s00249-009-0459-4
  25. Larson, S. M. & Davidson, A. R. The identification of conserved interactions within the SH3 domain by alignment of sequences and structures. Protein Sci. 9, 2170–2180 (2000). · DOI · Paper page
  26. Staub, O. & Rotin, D. WW domains. Structure 4, 495–499 (1996). · DOI
  27. Ball, L. J., Jarchau, T., Oschkinat, H. & Walter, U. EVH1 domains: structure, function and interactions. FEBS Lett. 513, 45–52 (2002). · DOI · Paper page
  28. O’Brate, A. & Giannakakou, P. The importance of p53 location: nuclear or cytoplasmic zip code? Drug Resist. Updat. 6, 313–322 (2003). · DOI · Paper page
  29. Moll, U. M. & Petrenko, O. The MDM2-p53 interaction. Mol. Cancer Res. 1, 1001–1008 (2003).
  30. Rodriguez, M. S., Desterro, J. M., Lain, S., Lane, D. P. & Hay, R. T. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 20, 8458–8467 (2000). · DOI · Paper page
  31. Sharma, A., Singh, K. & Almasan, A. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol. Biol. 920, 613–626 (2012). · DOI · Paper page
  32. Kurz, E. U., Douglas, P. & Lees-Miller, S. P. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J. Biol. Chem. 279, 53272–53281 (2004). · DOI · Paper page
  33. Huang, C. et al. Vanadate induces p53 transactivation through hydrogen peroxide and causes apoptosis. J. Biol. Chem. 275, 32516–32522 (2000). · DOI · Paper page
  34. Oneyama, C., Nakano, H. & Sharma, S. V. UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug. Oncogene 21, 2037–2050 (2002). · DOI
  35. Oneyama, C. et al. Synthetic inhibitors of proline-rich ligand-mediated protein-protein interaction: potent analogs of UCS15A. Chem. Biol. 10, 443–451 (2003). · DOI
  36. Cechowska-Pasko, M., Palka, J. & Wojtukiewicz, M. Z. Enhanced prolidase activity and decreased collagen content in breast cancer tissue. Int. J. Exp. Pathol. 87, 289–296 (2006). · DOI
  37. Lawenda, B. D. et al. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J. Natl. Cancer Inst. 100, 773–783 (2008). · DOI · Paper page
  38. D’Andrea, G. M. Use of antioxidants during chemotherapy and radiotherapy should be avoided. CA Cancer J. Clin. 55, 319–321 (2005). · DOI · Paper page
  39. Baptiste, N., Friedlander, P., Chen, X. & Prives, C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 21, 9–21 (2002). · DOI
  40. Venot, C. et al. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17, 4668–4679 (1998). · DOI · Paper page
  41. Murphy, M. et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 13, 2490–2501 (1999). · DOI · Paper page
  42. Zilfou, J. T., Hoffman, W. H., Sank, M., George, D. L. & Murphy, M. The corepressor mSin3a interacts with the proline-rich domain of p53 and protects p53 from proteasome-mediated degradation. Mol. Cell. Biol. 21, 3974–3985 (2001). · DOI · Paper page
  43. Dornan, D., Shimizu, H., Burch, L., Smith, A. J. & Hupp, T. R. The proline repeat domain of p53 binds directly to the transcriptional coactivator p300 and allosterically controls DNA-dependent acetylation of p53. Mol. Cell. Biol. 23, 8846–8861 (2003). · DOI · Paper page
  44. Zheng, H. et al. The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature 419, 849–853 (2002). · DOI · Paper page
  45. Berger, M., Stahl, N., Del Sal, G. & Haupt, Y. Mutations in proline 82 of p53 impair its activation by Pin1 and Chk2 in response to DNA damage. Mol. Cell. Biol. 25, 5380–5388 (2005). · DOI · Paper page
  46. Berger, M., Vogt Sionov, R., Levine, A. J. & Haupt, Y. A role for the polyproline domain of p53 in its regulation by Mdm2. J. Biol. Chem. 276, 3785–3790 (2001). · DOI · Paper page
  47. Tsvetkov, P., Reuven, N. & Shaul, Y. Ubiquitin-independent p53 proteasomal degradation. Cell. Death. Differ. 17, 103–108 (2010). · DOI
  48. Forlino, A. et al. Mutation analysis of five new patients affected by prolidase deficiency: the lack of enzyme activity causes necrosis-like cell death in cultured fibroblasts. Hum. Genet. 111, 314–322 (2002). · DOI
  49. Lupi, A. et al. Molecular characterisation of six patients with prolidase deficiency: identification of the first small duplication in the prolidase gene and of a mutation generating symptomatic and asymptomatic outcomes within the same family. J. Med. Genet. 43, e58 (2006). · DOI
  50. Besio, R. et al. Kinetic and structural evidences on human prolidase pathological mutants suggest strategies for enzyme functional rescue. PLoS ONE 8, e58792 (2013). · DOI
  51. Rossi, M. R. et al. The immortalized UROtsa cell line as a potential cell culture model of human urothelium. Environ. Health Perspect. 109, 801–808 (2001). · DOI · Paper page

Cited by

See all 29

Metadata

Authors
Yang, L., Li, Y., Bhattacharya, A., & Zhang, Y.
Venue
Nature Communications
Published
2017-12-12
Volume
8
Issue
1
ISSN
2041-1723
Cited by
29
References
8
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PEPD is a pivotal regulator of p53 tumor suppressor. https://app.cochat.ai/papers/10.1038/s41467-017-02097-9
The paper
Yang, L., Li, Y., Bhattacharya, A., & Zhang, Y. (2017). PEPD is a pivotal regulator of p53 tumor suppressor. Nature Communications. https://doi.org/10.1038/s41467-017-02097-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.